A review of current drug targets and pharmacology of antipsychotic treatment

Medicinal Chemistry Reviews - Online

Volumn 2, Issue 3, 2005, Pages 177-182

  Conley, Robert R ^a   Kelly, Deanna L ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

Antipsychotics; Aripiprazole; Clozapine; Mechanism of action; Olanzapine; Quetiapine; Risperidone; Schizophrenia; Ziprasidone

Indexed keywords

2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; AMPA RECEPTOR; ARIPIPRAZOLE; ASENAPINE; BIFEPRUNEX; BIFEPRUNOX; BLONANSERIN; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; E 5826; FARAMPATOR; HALOPERIDOL; ILOPERIDONE; KETAMINE; LAX 101; NEUROLEPTIC AGENT; NEUROPEPTIDE; NICOTINIC RECEPTOR; OLANZAPINE; OSANETANT; PHENCYCLIDINE; QUETIAPINE; RISPERIDONE; SECRETIN; SEROTONIN 2A ANTAGONIST; SEROTONIN ANTAGONIST; SERTINDOLE; TALNETANT; UNCLASSIFIED DRUG; ZIPRASIDONE;

AGRANULOCYTOSIS; ANTICHOLINERGIC EFFECT; BRAIN; CLINICAL TRIAL; COGNITIVE DEFECT; DOPAMINERGIC SYSTEM; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; ENURESIS; EXTRAPYRAMIDAL SYMPTOM; HOSPITALIZATION; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; HYPERTRIGLYCERIDEMIA; NAUSEA AND VOMITING; NEGATIVE SYNDROME; NERVE TRACT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; QT PROLONGATION; RECEPTOR BLOCKING; RECURRENCE RISK; RELAPSE; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; TARDIVE DYSKINESIA; WEIGHT GAIN;

EID: 23944493686     PISSN: 15672700     EISSN: 15672700     Source Type: Journal    
DOI: 10.2174/1567203054065709     Document Type: Review

References (62)

1. Buchanan, R.W.; Brier, A.; Kirkpatrick, B.; Elkashef, A.; Munson, R.C.; Gellad, F. and Carpenter, W.T. Jr. Am. J. Psychiatry, 1993, 150, 59-65.
2. Gur, R.E. and Pearlson, G.D. Schizophr. Bull., 1993, 19, 337-53.
3. Tamminga, C.A.; Thaker, G.K.; Buchanan, R.; Kirkpatrick, B; Alphs, L.D.; Chase, T.N. and Carpenter, W.T. Arch. Gen. Psychiatry, 1992, 49(7), 522-30.
4. Liddle, P.F.; Friston, K.J.; Frith, C.D.; Hirsch, S.R.; Jones, T. and Frackowiak, R.S. Br. J. Psychiatry, 1992, 160, 179-86.
5. Green, M.F. Am. J. Psychiatry, 1996, 153, 321-30.
6. Carlsson, A. Science, 2001, 294, (5544), 1021-4.
7. Snyder, S.H. Am. J. Psychiatry, 1976, 33(2),197-202.
8. Seeman, P.; Lee, T.; Chau-Wong, M. and Wong, K. Nature, 1976, 261, 717-719.
9. Kapur, S.; Zipursky, R.; Jones, C.; Shammi, C.S.; Remington, G. and Seeman, P. Arch. Gen. Psychiatry, 2000, 57, 553-559.
10. Heritch, A.J. Schizophr. Bull., 1990, 16, 605-615.
11. Marder, S.R.; Wirshing, W. and Van Putten, T. Schizophr. Res., 1991, 4, 81-90.
12. Kane, J.M. Biol. Psychiatry, 1999, 46(10),1396-408.
13. Sedvall, G.C. Int. Clin. Psychopharmacol., 1996, 11(suppl 2), 41-46.
14. Dray, A.; Gonye, T.J.; Oakley, N.R. and Tanner, T. Brain Res., 1976, 113, 45-57.
15. Soubrie, P.; Reisine, T.D. and Glowinski, J. Neuroscience, 1984, 131, 615-624.
16. Dewey, S.L.; Smith, G.S.; Logan, J.; Alexoff, D.; Ding, Y.S.; King, P.; Pappas, N.; Brodie, J.D. and Ashby, C.R. Jr. J. Neurosci., 1995, 15, 821-829.
17. Meltzer, H.Y. Clin. Neurosci., 1995, 3, 64-75.
18. Reynolds, G.P. Trends Pharmacol. Sci., 1992, 13, 116-121.
19. Monsma, F.J.; Shen, Y.; Ward, R.P.; Hamblin, M.W. and Sibley, D.R. Mol. Pharmacol., 1993, 43, 320-327.
20. Roth, B.L.; Craigo, S.C.; Choudhary, M.S.; Uluer, A.; Monsma, F.J. Jr.; Shen, Y.; Meltzer, H.Y. and Sibley, D.R. J. Pharmacol. Exp. Ther., 1994, 268, 1403-1410.
21. Canton, H.; Verriele, L. and Colpaert, F.C. Eur. J. Pharmacol., 1990, 191, 93-96.
22. Olney, J.W. and Farber, N.B. Arch. Gen. Psychiatry, 1995, 52, 998-1007.
23. Tamminga, C.A. Crit. Rev. Neurobiol., 1998, 12, 21-36.
24. Casey, D.E. Int. Clin. Psychopharmacol., 1995, 10(suppl 3), 105-114.
25. Hippius, H. Psychopharmacology, 1989, 99, S3-S5.
26. Pickar, D.; Owen, R.R.; Litman, R.E.; Konicki, E.; Gutierrez, R. and Rapaport, M.H. Arch. Gen. Psychiatry, 1992, 49, 345-353.
27. Conley, R.R. and Buchanan, R.W. Schizophr. Bull., 1997, 23(4), 663-674.
28. Kane, J.; Honigfeld, G.; Singer, J. and Meltzer, H. Arch. Gen. Psychiatry, 1988, 45, 789-796.
29. Conley, R.R.; Carpenter, W.T. Jr. and Tamminga, C.A. Am. J. Psychiatry, 1997, 154(9),1243-7.
30. Conley, R.R.; Tamminga, C.A.; Kelly, D.L. and Richardson, C.M. Biol. Psychiatry, 1999, 46(1), 73-7.
31. Kane, J.M.; Marder, S.R.; Schooler, N.R.; Wirshing, W.C.; Umbricht, D.; Baker, R.W.; Wirshing, D.A.; Safferman, A.; Ganguli, R.; McMeniman, M. and Borenstein, M. Arch. Gen. Psychiatry, 2001, 58(10), 965-72.
32. Meltzer, H.Y. J. Clin. Psychiatry, 1999, 60(Suppl 12), 47-50.
33. Conley, R.R. J. Clin. Psychiatry, 1998, 59(3), 44-8.
34. Wahlbeck, K.; Cheine, M. and Essali, M.A. Cochrane Database Syst. Rev., 2000, (2),CD000059.
35. Schotte, A.; Janssen, P.F.M.; Gommeren, W.; Luyten, W.H.M.L.; Van Gompel, P.; Lesage, A.S.; De Loore, K. and Leysen, J.E. Psychopharmacology, 1996, 124, 57-73.
36. Marder, S.R.and Meibach, R.C. Am. J. Psychiatry, 1994, 151, 825-835.
37. Marder, S.R.; Davis, J.M. and Chouinard, G. J. Clin. Psychiatry, 1997, 58, 538-546.
38. Love, R.C.; Conley, R.R.; Kelly, D.L. and Bartko, J.J. J. Clin. Psychiatry, 1999, 60, 771-775.
39. Conley, R.R. and Mahmoud, R. Am. J. Psychiatry, 2001, 158, 765-74.
40. Ho, B.C.; Miller, D.; Nopoulos, P. and Andreasen, N.C. J. Clin. Psychiatry, 1999, 60, 658-63.
41. Wirshing, D.A.; Marshall, B.D.; Green, M.F.; Montz, J.; Marder, S.R. and Wirshing, W.C. Am. J. Psychiatry, 1999, 156, 1374-9.
42. Owens, D.G.C. J. Clin. Psychiatry, 1994, 55(suppl 5), 29-35.
43. Stanniland, C. and Taylor, D. Drug Safety, 2000, 22(3), 195-214.
44. Csernansky, J.G.; Mahmoud, R. and Brenner, R. N. Engl. J. Med., 2002, 346(1), 16-22.
45. Conley, R.R.; Tamminga, C.A.; Bartko, J.J.; Richardson, C.; Peszke, M.; Lingle, J.; Hegerty, J.; Love, R.; Gounaris, C. and Zaremba, S. Am. J. Psychiatry, 1998, 155, 914-920.
46. Bymaster, F.P.; Calligaro, D.O.; Falcone, J.F.; Marsh, R.D.; Moore, N.A.; Tye, N.C.; Seeman, P. and Wong, D.T. Neuropsychopharmacology, 1996, 14, 87-96.
47. Beasley, C.M.; Tollefson, G.; Tran, P.; Satterlee, W.; Sanger, T. and Hamilton, S. Neuropsychopharmacology, 1996, 14, 111-123.
48. Tollefson, G.D.; Beasley, C.M.; Tran, P.V.; Street, J.S.; Krueger, J.A.; Tamura, R.N.; Graffeo, K.A. and Thieme, M.E. Am. J. Psychiatry, 1997, 154(4), 457-65.
49. Bhana, N. and Perry, C.M. CNS Drugs, 2001, 15(11), 871-904.
50. Melkersson, K.I.; Hulting, A.L and Brismar, K.E. J. Clin. Psychiatry, 2000, 61, 742-9.
51. Wirshing, D.A.; Wirshing, W.C.; Kysar, L.; Berisfor, M.A.; Goldstein, D.; Pashdag, J.; Mintz, J. and Marder, S.R. J. Clin. Psychiatry, 1999, 60, 358-63.
52. Wirshing, D.A.; Pierre, J.M.; Eyeler, J.; Weinbach, J. and Wirshing, W.C. Biol. Psychiatry, 2001, 50, 148-9.
53. Arvanitis, L.A.; Miller, B.G.; and the Seroquel Trial 13 Study Group. Biol. Psychiatry, 1997, 42, 233-246.
54. Small, J.G.; Hirsh, S.R.; Arvanitis, L.A.; Miller, B.G.; Link, C.G.C. and the Seroquel Study Group. Arch. Gen. Psychiatry, 1997, 54, 549-557.
55. Seeger,T.; Seymour, P.A.; Schmidt, A.W.; Zorn, S.H.; Schulz, D.W.; Lebel, L.A.; McLean, S.; Guanowsky, V.; Howard, H.R. and Lowe, J.A. 3rd. J. Pharmacol. Exp. Ther., 1995, 275, 101-113.
56. Keck, P.; Buffenstein, A. Ferguson, J.; Feighner, J.; Jaffe, W.; Harrigan, E.P. and Morrissey, M.R. Psychopharmacology, 1998, 140, 173-184.
57. Daniel, D.G.; Zimbroff, D.L.; Potkin, S.G.; Reeves, K.R.; Harrigan, E.P. and Lakshminarayanan, M. Neuropsychopharmacology, 1999, 20, 491-505.
58. Shapiro, D.A.; Renock, S.; Arrington, E.; Chiodo, L.A.; Liu, L.X.; Sibley, D; Roth, B.L.; Mailman, R.; Neuropsychopharmacology, 2003, 28, 1400-11.
59. Winans, E. Am. J. Health Syst. Pharm., 2003, 60, 2437-45.
60. Wolf, W. Curr. Opin. Investig. Drugs, 2003, 4, 72-76.
61. Oka, M.; Noda, Y.; Ochi, Y.; Furukawa, K.; Une, T.; Kurumiya, S.; Hino, K.; Karasawa, T. J. Pharmacol. Exp. Ther., 1993, 264, 158-65.
62. Andree, B.; Halldin, C.; Vrijmoed-de Vries, M.; Farde, L. Psychopharmaocology, 1997, 131, 339-45.